Abstract:A series of 1H‐benzimidazole‐4‐carboxamide PARP‐1 inhibitors using different saturated nitrogen‐containing heterocycles as linker groups was designed synthesized and evaluated its anti‐proliferation activities of MDA‐MB‐436 cell to obtain the preferred structures of linker group and terminal group in the AD site. PARP‐1 inhibitors have been successfully applied in the clinical treatment of various cancer. Side effects and drug resistant cases were reported, and more effective PARP‐1 inhibitors were required. However, studies on the AD site of PARP‐1 inhibitors are currently incomplete. Therefore, to synthesize more potential candidate PARP‐1 inhibitors and disclose some AD site SAR of the PARP‐1 inhibitors, herein, a series of 2‐phenyl‐benzimidazole‐4‐carboxamide derivatives using different saturated nitrogen‐contained heterocycles as linker group (6a‐6t) have been designed, synthesized and evaluated PARP‐1 inhibitory activity and proliferation inhibitory against BRCA‐1 mutant MDA‐MB‐436 cell line in vitro. The results showed 6b (IC50 = 8.65 nM) exhibited the most PARP‐1 enzyme inhibitory activity comparable with Veliparib (IC50 = 15.54 nM) and Olaparib (IC50 =2.77 nM); 6m exhibited the strongest MDA‐MB‐436 cell anti‐proliferation activity (IC50=25.36±6.06 μM) comparable with Olaparib (IC50 = 23.89±3.81 μM). The compounds 6b, 6r, and 6m could be potential candidates for effective PARP‐1 inhibitors and valuable for further optimization. The analysis of activity data also showed that the holistically anti‐proliferation activity of the 1,4‐diazepane group was about~2 fold than that of the piperazine group. Meanwhile, the terminal 3‐methyl‐furanyl group exhibited the most robust PARP‐1 inhibitory and anti‐proliferation activity. It's hoped that the results could benefitable for further optimization of PARP‐1 inhibitors. Furthermore, we note that some compounds (6d,6g,6n,6p,6s) showed poor PARP‐1 inhibitory (>500 nM) but relatively good anti‐proliferation activity, which indicates the proliferation inhibitory mechanism against MDA‐MB‐436 cell line was worth investigating in‐depth.

Design, Synthesis and Evaluation of Phthalazinone Thiohydantoin-Based Derivative As Potent PARP-1 Inhibitors.

Design, synthesis and antitumor activities of phthalazinone derivatives as PARP-1 inhibitors and PARP-1/HDAC-1 inhibitors

Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents

YCH1899, a Highly Effective Phthalazin-1(2 H )-one Derivative That Overcomes Resistance to Prior PARP Inhibitors

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-d]pyrimidine-4(3H)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Discovery of Novel Bromophenol Thiosemicarbazone Hybrids As Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone

Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor

Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.

Design, Synthesis, and Evaluation of 1H‐benzo[d]imidazole‐4‐carboxamide PARP‐1 Inhibitors Using Different Saturated Nitrogen‐Contained Heterocycle as linker Group

Synthesis and In Silico Evaluation of Piperazine-Substituted 2,3-Dichloro-5,8-dihydroxy-1,4-naphthoquinone Derivatives as Potential PARP-1 Inhibitors

Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer

Identification of [1,2,4]Triazolo[4,3- a ]pyrazine PARP1 inhibitors with overcome acquired resistance activities

Design, Synthesis and Antitumor Activity Study of PARP-1/HDAC Dual Targeting Inhibitors.

Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors